Pharmaceutical Executive, Feb 1, 2010 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Feb 1, 2010
Features
Brand of the Year: Avastin
By William Looney
As Genentech's Avastin continues to mature and spread its branches, the company is looking for high profits on the back end.
Tearing Up the Rule Book
By Carrie Fisher, Hay Group
Sales compensation practices are due for an overhaul in 2010.
Shire on the Wire
By Walter Armstrong
The British specialty shop was once a laughing stock. Now it’s one of pharma’s fastest growing mid-size firms, with a patent cliff bridged and a biotech engine of orphan drugs. So why does CEO Angus Russell fret that success might spoil Shire?
Columns
A Sturdy Framework
Improving field force business planning requires managers to run each sales territory as if it is a self-contained business operation.
Global
New Challenges for NICE
By Julian Upton
Last year was a trying one for the UK's National Institute for Health and Clinical Excellence. Will 2010 be any easier
From the Editor
Assets for Advantage
By William Looney
Innovation won't happen until the industry is ready to sit down and make a big change.
Washington Report
Vaccines and Value
By Jill Wechsler
R&D is surging, but new methods and data raise new manufacturing and regulatory challenges.

ADVERTISEMENT

Click here